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Factor V Antigen Levels and Venous Thrombosis
Risk Profile, Interaction With Factor V Leiden, and Relation With Factor
VIII Antigen Levels
P.W. Kamphuisen, F.R. Rosendaal, J.C.J. Eikenboom, R. Bös, R.M. Bertina
Abstract—Clotting factor V has a dual function in coagulation: after activation, procoagulant factor V stimulates the
formation of thrombin, whereas anticoagulant factor V acts äs a cofactor for activated protein C (APC) in the
degradation of factor VHI/VIIIa, thereby reducing thrombin formation. In the present study, we evaluated whether
plasma factor V levels, either decreased or increased, are associated with venous thrombosis. High procoagulant factor
V levels may enhance prothrombinase activity and increase the thrombosis risk. Low anticoagulant factor V levels could
reduce APC-cofactor activity in the factor VIII inactivation (APC-resistant phenotype), which might also promote
thrombosis. Low factor V levels in combination with factor V Leiden could lead to a more severe APC-resistant
phenotype (pseudohomozygous APC resistance). To address these issues, we have measured factor V antigen (factor
V: Ag) levels in 474 patients with thrombosis and 474 control subjects that were part of the Leiden Thrombophilia Study
(LETS). Factor V:Ag levels increased by 7.6 U/dL for every successive 10 years of age. Mean factor V:Ag levels were
134 (ränge 41 to 305) U/dL in patients and 132 (ränge 47 to 302) U/dL in controls. Neither high nor low factor V:Ag
levels were associated with venous thrombosis. We found that factor V:Ag and factor VIII antigen levels in plasma were
correlated, but factor V did not modify the thrombotic risk of high factor VIII levels. The normalized APC ratio was
not influenced by the factor V:Ag level in subjects with or without factor V Leiden. We conclude that neither low nor
high factor V:Ag levels are associated with venous thrombosis and that factor V:Ag levels do not mediate the thrombotic
risk associated with high factor VIII levels. (Arterioscler Thromb Vase Biol. 2000;20:1382-1386.)
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Deep-vein thrombosis is a common disorder with anincidence in the general population of «*! in 1000
individuals per year.1·2 Despite growing insight into inherited
äs well äs acquired risk factors for thrombosis, the cause of
many thrombotic episodes remains unknown. A single point
mutation in the factor V gene (G 1691 A, R506Q, factor V
Leiden)3 results in a reduced sensitivity of plasma factor Va
to inactivation by activated protein C (APC)4 and is present in
«=20% of white patients with deep-vein thrombosis.5 Coagu-
lation factor V has a central role in procoagulant and
anticoagulant pathways: factor V is activated by factor Xa or
thrombin6-8 and markedly accelerates the activation of pro-
thrombin by factor Xa before factor Va is degraded by
APC.9·10 In addition, factor V (but not factor Va) has been
reported to act äs a cofactor of APC in the proteolytic
degradation of both factor VIII and factor Villa.4·1'-13
Whether the level of factor V in plasma affects the risk of
thrombosis is unclear, although, hypothetically, high äs well
äs low factor V levels may increase the thrombotic risk.
Elevated factor VIII levels are associated with an increased
risk for thrombosis,14 and factor V is, like factor VIII, an
important cofactor in one of the Steps of the coagulation
cascade. Therefore, high plasma levels of factor V might lead
to an increased prothrombinase activity and increased risk of
thrombosis. In 1966, Gaston15 reported a family with an
association between elevated factor V levels and venous
thrombosis.
Low factor V levels are associated with a reduced APC
cofactor activity in the inactivation of factor VHI/VIIIa.11-13
This results in an APC-resistant phenotype and therefore
might be associated with an increased risk of thrombosis,
especially when the factor V/factor VIII ratio is low. In that
case, low factor V levels would increase the risk of
thrombosis.
Finally, we have to consider the influence of factor V
levels on the thrombotic risk of carriers of factor V Leiden.
Reduced expression of factor V by the non-factor V Leiden
allele (low factor V levels) might result in a more severe
APC-resistant phenotype, äs has been reported for patients
pseudohomozygous for APC resistance (combined heterozy-
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gous factor V deficiency and heterozygous factor V Leiden
mutation).16-19 Similarly, enhanced expression of factor V by
the non-factor V Leiden allele (high factor V levels) might
result in a less severe APC-resistant phenotype.
To address these issues, we measured the factor V antigen
(factor V:Ag) level in 474 patients with thrombosis and 474




The patients and control subjects included in the present study came
frorn a population-based case-control study of venous thrombosis
(LETS).20 The present study includes 474 unselected consecutive
outpatients aged <70 years who were treated with anticoagulants
after a first episode of objectively confirmed deep-vein thrombosis
and who did not have an underlying malignancy. The median time
between the occurrence of the deep-vein thrombosis and blood
collection was 18 months (ränge 6 to 48 months). Each thrombotic
patient provided his or her own sex- and age-matched healthy control
subject according to predefined criteria.14 The mean age for patients
and controls was 47 years (ränge 16 to 70 years for patients and 16
to 73 years for controls).
Blood Collection and Plasma Assays
Blood was collected in tubes containing 0.106 mmol/L trisodium
citrate. Plasma was prepared by centrifugation for 10 minutes at
2000g at room temperature and stored at -70°C in 1.5 mL aliquots.
Factor V:Ag was measured by an in-house-developed sandwich-
type ELISA with 2 monoclonal antibodies, both with a high affinity
for (activated) factor V. The monoclonal antibodies, denoted V-6 and
V-9, were selected from a panel of antibodies isolated on the light
chain of factor V, äs demonstrated by Western blot analysis with the
use of purified factor Va under reducing conditions. Ninety-six-well
plates were coated with monoclonal antibody V-6 (at a concentration
of 3 mg/mL in 0.1 mol/L NaHCO3 and 0.5 mol/L NaCl, pH 9.0) and
left overnight at 4°C. Plasma samples were diluted 1/100 to 1/400 in
0.05 mol/L triethanolamine, 0.1 mol/L NaCl, 0.01 mol/L EDTA, and
0.1% Tween 20, pH 7.5, and 100 μι per sample was incubated for
3 hours in the coated wells. Monoclonal antibody V-9, labeled with
horseradish peroxidase (Zymed Laboratories Ine) and diluted to 2
mg/mL in 0.05 mol/L triethanolamine, 0.1 mol/L NaCl, 0.01 mol/L
EDTA, and 0.1% Tween 20, pH 7.5, was used for the detection of
immobilized factor V (2-hour incubation). In the final step,
0.42 mmol/L 3,3',5,5'-tetramethylbenzidine, 0.1 mol/L sodium ace-
tate, and 1.1 mol/L H2O2, pH 5.5, were added, and the reaction was
stopped after 20 minutes with 100 μι H2SO4. After every step, plates
were washed 4 times with 0.05 mol/L triethanolamine, 0.1 mol/L
NaCl, and 0.1% Tween 20, pH 7.5. Pooled normal plasma (PNP),
prepared from the plasma of 60 healthy volunteers (mean age 40
years) and diluted 1/50 to 1/3200, was used äs a reference and
defined to contain 100 U/dL. In each analytical run, we included 2
samples of an in-house PNP and 2 samples of a commercial high
factor V plasma (Mallinckrodt Baker) äs controls. PNP contained, on
average, 103±8 U/dL factor V:Ag (interassay Variation 8.2%,
intra-assay Variation 6.7%). High factor V plasma contained, on
average, 136±12 U/dL factor V:Ag (interassay Variation 8.9%,
intra-assay Variation 5.2%). Results were the same for plasma and
serum samples (after correction for the dilution with the anticoagu-
lant) of the same individual and not substantially altered by repeated
freezing and thawing.
Factor VIII antigen levels have been measured by a sandwich-type
ELISA with two monoclonal antibodies directed against the light
chain of factor VIII.21 CLB Cag 117 was used äs a catching antibody,
and CLB-A was used äs a tagging antibody. Both antibodies were
kiridly provided by Dr J.A. van Mourik (Department of Blood
Coagulation, CLB, Sanquin Blood Supply Foundation, Amsterdam,
the Netherlands). PNP, calibrated against the World Health Organi-
zation Standard (91/666 ratio) for factor VIII antigen (factor VII-
I:Ag), was used äs a reference. The sensitivity of plasma to APC was






























determined äs previously described22 and expressed in a normalized
APC sensitivity ratio.22
Statistical Analysis
An unconditional logistic model was used to calculate odds ratios
(ORs) äs a measure of relative risk with 95% CIs derived from the
model. This OR estimates the risk of venous thrombosis in the
presence of a risk factor relative to the absence of the particular risk
factor, the reference category. Factor V and factor VIII levels were
entered into the logistic model äs categorized variables. The cutoff
points were 100, 125, and 150 U/dL for factor VIII and 110, 130, and




The total mean factor V:Ag level was 132 U/dL, with a ränge
between 41 to 305 U/dL. The factor V:Ag levels were
normally distributed. In multiple regression, age and smoking
were associated with the plasma factor V:Ag level. For every
successive 10 years of age, the factor V:Ag level increased
7.6 (95% CI 6.1 to 9.1) U/dL. Smokers had 8.3 (95% CI 4.0
to 12.6) U/dL higher factor V:Ag levels than did nonsmokers.
Factor V:Ag Levels and Venous Thrombosis
The mean factor V:Ag level was 134 (ränge 41 to 305) U/dL
for the patients and 132 (ränge 47 to 302) U/dL for the
controls. Table l presents the ORs of patients and controls
after stratification of the factor V: Ag levels into 4 groups. The
relative risk of factor V:Ag levels >150 U/dL was 1.3 (95%
CI 0.9 to 1.8) compared with the reference category (factor
V:Ag level <110 U/dL). The data of Table l also show that
reduced factor V levels are not associated with an increased
risk of thrombosis. The influence on thrombosis of either low
or high factor V:Ag levels was analyzed in more detail by
stratification of the patients and controls into 10 groups; we
calculated the relative risk for the patients with high factor
V:Ag compared with the lowest category of factor V:Ag
(<93 U/dL). Even the highest factor V: Ag level (> 171 U/dL)
was not associated with an increased risk of thrombosis
compared with the reference category (Figure 1). The same
was true for the lowest factor V:Ag category; even factor V
levels <70 U/dL did not increase the risk of thrombosis.
Interaction Factor V:Ag Levels and Factor
V Leiden
Factor V Leiden was determined in 945 of the 948 subjects.
In 3 patients, DNA was unavailable. One hundred six subjects
carried the factor V Leiden mutation, of whom 8 were
homozygous. The factor V:Ag level (mean±SD) was
132±34 U/dL for wild-type factor V, 137±33 U/dL for
heterozygous factor V Leiden, and 146 ±42 U/dL for ho-




TABLE 3. Combined Effects of Factor V and Factor VIII Levels
on Thrombotic Risk
Factor V :Ag, Factor VIII: Ag, Patients, Controls,
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Figure 1. Risk of thrombosis (+95% CIs) for 10 categories of
factor V:Ag levels. Reference category is factor V:Ag <93 U/dL.
mozygous camers of factor V Leiden. These groups were
entered in a regression model (0 represents wild-type factor
V; l, heterozygous factor V Leiden; and 2, homozygous
factor V Leiden) with factor V:Ag äs a dependent variable;
the regression coefficient β was 5.1 (95% CI -l to 11).
Further analyses explored the association between factor V
Leiden and venous thrombosis for different factor V:Ag
levels. Because only 8 subjects were homozygous for factor
V Leiden, calculations for factor V Leiden carriers were
based on homozygous and heterozygous carriers äs a single
group. For carriers of factor V Leiden who had factor V:Ag
levels >150 U/dL, the risk of venous thrombosis increased
nearly 13-fold (95% CI 3.8 to 41) compared with carriers of
wild-type factor V with factor V:Ag levels <110 U/dL (Table
2). (This risk is not very different from the risk of factor V
Leiden carriers with factor V antigen levels <150 U/dL,
especially when we realize that the calculations in Table 2 are
based on relatively low numbers in the control group.
Relation Between Factor V:Ag and Factor
VIII:Ag Levels
Factor V and factor VIII are related proteins and probably
share common biosynthetic pathways, äs reflected by the
identification of patients with combined factor V and factor
VIII deficiency.23-25 It was of interest to analyze to what
extent factor V and VIII levels in plasma are correlated. We
found that factor VIII levels and factor V levels are correlated
(r=0.26, P<0.001). For carriers of the wild-type factor V,
factor VIILAg rose by 3.5 U/dL for every 10-U/dL increase
in factor V:Ag, whereas for factor V Leiden carriers, the
factor VIILAg level increased by 4.6 U/dL. Adjustment for
age and separate analysis in thrombotic patients and controls
yielded the same results.
Next, we investigated whether the effect of high factor VIII
levels on thrombosis is conditional on the factor V level.
Because factor V Leiden itself is a risk factor for thrombosis,
analysis was restricted to carriers of the normal factor V
genotype. For these calculations, we took the highest quar-
tiles of factor V and factor VIII and compared them with the
lowest quartiles. Table 3 shows that factor VIII levels >150
U/dL in combination with factor V levels < 110 U/dL gave an
OR of 2.2. The combination of factor V and VIII levels > 150
U/dL increased the thrombotic risk 6.0 (95% CI 2.6 to 12)
times compared with factor V levels <110 U/dL and factor
VIII levels <100 U/dL (Table 3). This risk is similar to the
previously reported 6-fold increase in the risk of thrombosis
for unadjusted factor VIILAg levels >150 U/dL,21 indicating
that high factor VIILAg does not interact with high factor
V:Ag levels in promoting thrombosis.
Factor V:Ag Levels and APC Ratio
The association of factor V:Ag levels and the normalized
APC ratio in subjects with normal factor V and factor V
Leiden is illustrated in Figure 2. Patients using oral antico-
agulants (n=48) or with a lupus anticoagulant (n=4) were
excluded from this analysis because they have a prolonged
activated partial thromboplastin time in the absence of APC,
which gives unreliable results in the APC resistance test. In
factor V Leiden and factor V wild-type subjects, factor V:Ag













































*ln 3 patients, DNA was unavailable.
fReference categories are noncarners with factor V:Ag levels <110 U/dL. Age-adjusted logistic
regression led to similar results.
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Figure 2. Distribution of normaiized APC sensitivity ratios for
Aiild-type factor V (·) and factor V Leiden (D) in relation to fac-
:or V:Ag levels.
levels had no effect on the APC ratio (r=0.01 for factor V
Leiden, r=—0.04 for wild-type factor V).
Discussion
The present study evaluates the relation between factor V
levels and venous thrombosis in a large population-based
:ase-control study. Factor V:Ag levels were found to be
influenced by age and smoking. The 7.6-U/dL increase in
factor V that we found for every successive 10 years of age
is in agreement with the findings of Brozovic et al,26 who
reported an increase in factor V activity of 0.6% per year (=6
U/dL per decade).
Factor V:Ag levels were measured by ELISA with the use
of 2 monoclonal antibodies against the light chain of factor V.
The mean factor V:Ag level of the control group was 132
U/dL higher than we would have expected. Our PNP con-
cained, on average, 103 U/dL factor V. The intra-assay and
mterassay Variation were relatively low and very acceptable
for this type of test.
Neither low nor high factor V:Ag levels in plasma were
associated with venous thrombosis. Apparently, unlike factor
VIII,14 high levels of plasma procoagulant factor V do not
promote venous thrombosis, nor do reduced levels of antico-
agulant factor V. It is possible that this is related to a balance
between the procoagulant and anticoagulant functions of
factor V; a high factor V level may enhance prothrombinase
activity, äs does factor V Leiden,27 but at the same time, high
anticoagulant factor V may result via its APC-cofactor
activity in an increased degradation of factor VIII/VIIIa.n~13
The present study provides no information on the role of
platelet factor V in the pathogenesis of venous thrombosis.
Platelet factor V has been implicated äs an important regu-
lator of hemostasis in vivo.28 Recently, however, the origin of
platelet factor V (biosynthesis in platelets or endocytosis of
plasma factor V by platelets) has been questioned.29·30 More
information is required to determine how platelet factor V
concentrations relate to plasma factor V levels before we can
discuss an independent role of platelet factor V in thrombosis.
The conclusion that low factor V levels are not associated
with venous thrombosis is not a complete surprise because of
the lack of reports on thrombotic events in heterozygous
factor V-deficient family members of patients with severe
factor V deficiency. Very recently, Redondo et al31 found that
high factor V activity levels are associated with arterial
thrombosis. No mechanism for this relation was provided.
Carriers of factor V Leiden with factor V:Ag levels >150
U/dL had a 13-fold increased risk compared with those with
wild-type factor V with factor V:Ag levels <110 U/dL.
Because this result is based on only 3 controls, we do not
believe that this indicates a higher risk for this group of factor
V Leiden carriers.
Factors V and VIII are related proteins and share common
biosynthetic pathways, äs reflected by recent studies of
Nichols and colleagues23 25 and Neerman-Arbez et al24 m
combined factor V and VIII deficiencies. In the present study,
we found that factor V:Ag levels correlate with plasma factor
VIILAg levels, suggesting that common posttranslational
modifications23 explain a small part of the large Variation in
plasma factor V levels and VIII levels. The thrombosis risk of
high factor VIII:Ag levels was not affected by factor V levels.
The combination of high factor V and high factor VIII levels
did not result in a higher thrombotic risk than that of high
factor VIII levels by themselves; thus, factor V does not
modify the thrombotic risk of elevated factor VIII levels.
The normaiized APC ratio was not influenced by the factor
V:Ag level in subjects with or without factor V Leiden.
Freyburger et al32 found slightly lower mean APC ratios for
thrombotic patients with factor V:C levels >\00% compared
with those with levels <100%. In healthy pregnant women,
results are conflicting: Walker et al" found no relation
between the APC ratio and factor V activity levels, whereas
Clark et al34 observed a relation (r=-0.33, P=0.03) after
excluding subjects with factor VIII:C levels >120 U/dL. In
our subjects, after adjustment for the mfluence of elevated
factor VIILAg levels, no relation between factor V and the
normaiized APC sensitivity ratio could be observed. Our data
suggest that the synthesis of factor V in subjects with factor
V Leiden is normal and that the elevation of the factor V:Ag
level does not affect the APC ratio in heterozygotes and
therefore cannot be considered äs a cause of acquired APC
resistance. We also found no relation between low factor V
levels and the APC sensitivity ratio, which is explained by the
fact that a reduction of the APC ratio occurs only at very low
factor V levels (<25%).3<i
In conclusion, factor V:Ag levels are not associated with a
risk of venous thrombosis. Factor V levels and factor VIII
levels are correlated in plasma, but factor V does not mediate
the thrombotic risk of high factor VIII levels. There seems to
be no clear relation between factor V:Ag levels and the
normaiized APC ratio in subjects with and without factor
V Leiden.
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